DiscoveryProbe™ FDA-approved Drug Library: Benchmark Resource for High-Throughput Drug Screening

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 bioactive compounds approved by global regulatory agencies, supporting high-throughput and high-content screening (HTS/HCS) for drug discovery (ApexBio). All compounds are provided as 10 mM DMSO solutions, stable for 12–24 months at -20°C to -80°C. The library encompasses diverse mechanisms, including enzyme inhibitors, receptor modulators, and ion channel regulators. It is validated for drug repositioning, target identification, and pathway interrogation, with applications spanning oncology, neurodegenerative diseases, and signal pathway studies (related content). Recent studies, such as the identification of carbenoxolone disodium as an HDAC6 inhibitor in gastric cancer, exemplify its translational impact (Song et al., 2023).

Biological Rationale

The DiscoveryProbe™ FDA-approved Drug Library is designed to accelerate translational research by providing a panel of compounds with known clinical and regulatory profiles. Over 2,300 molecules are included, each with established safety, pharmacokinetics, and documented mechanisms (see reference standard discussion). These compounds span a wide range of targets, including but not limited to kinases, GPCRs, ion channels, and enzymes. The inclusion criteria ensure that every compound has either FDA, EMA, HMA, CFDA, or PMDA approval, or is listed in major pharmacopeias, establishing a high baseline for quality and traceability. This foundation enables the library to support applications in disease modeling, target deconvolution, and experimental validation of pharmacological hypotheses. Enzyme inhibitors, receptor agonists/antagonists, and pathway modulators are especially well-represented, reflecting current priorities in drug repurposing and mechanistic research (source).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

Each compound within the DiscoveryProbe™ FDA-approved Drug Library acts via a characterized mechanism of action (MoA). Examples include:

• Doxorubicin: Topoisomerase II inhibitor, induces DNA double-strand breaks (PubChem).
• Metformin: AMPK activator, modulates cellular metabolism (PubChem).
• Atorvastatin: HMG-CoA reductase inhibitor, reduces cholesterol biosynthesis (PubChem).

In addition, recent literature demonstrates the utility of bioactive compound libraries in identifying novel mechanisms and off-target effects. For example, carbenoxolone disodium was recently characterized as an HDAC6 inhibitor, suppressing gastric cancer cell migration (IC₅₀ = 0.772 μM) (Song et al., 2023). Such findings underscore the value of comprehensive, well-annotated libraries for mechanistic discovery.

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library contains 2,320 compounds, each with documented regulatory approval or pharmacopeial listing (ApexBio product page).
• All compounds are supplied as pre-dissolved 10 mM solutions in DMSO, stable for 12 months at -20°C and 24 months at -80°C (Product documentation).
• Validated for high-throughput screening (HTS) and high-content screening (HCS) applications, supporting drug repositioning and target identification (BMS-626529.com).
• Carbenoxolone disodium from the library was identified as a novel HDAC6 inhibitor, with an IC₅₀ of 0.772 μM and K_D of 0.943 μM, suppressing gastric cancer cell migration in vitro and in vivo (Song et al., 2023).
• Multiple cancer, neurodegenerative, and metabolic disease models have been interrogated using the library for pharmacological target identification (Myelin Basic Protein article).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is widely used for:

• High-throughput screening (HTS) of pharmacologically active compounds in disease models.
• Drug repositioning campaigns, enabling the rapid identification of new indications for approved drugs.
• Target deconvolution and mechanism-of-action studies, particularly in oncology and neurodegenerative disease research (see translational strategy discussion).
• Signal pathway regulation analysis and validation of systems biology predictions.

However, certain limitations and misconceptions must be addressed.

Common Pitfalls or Misconceptions

• The library is not a substitute for primary screening of uncharacterized chemical matter; it is designed for repurposing and mechanistic studies of known compounds.
• Some compounds may have off-target effects not fully documented in the product annotation; confirmatory assays are recommended.
• High DMSO concentrations can affect cell viability; users must ensure final DMSO concentrations are compatible with their assay systems.
• The library does not cover investigational or preclinical compounds lacking regulatory approval.
• Interpretation of hits should consider the clinical pharmacokinetics and bioavailability of each compound, as in vitro activity may not translate in vivo.

This article updates and extends prior overviews (see this validated screening summary) by providing detailed, citation-linked evidence for the library's clinical and mechanistic breadth.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library supports seamless integration into HTS and HCS workflows. Compounds are supplied in multiple formats, including 96-well plates, deep-well plates, and 2D barcoded screw-top tubes, enabling compatibility with robotic liquid handling systems. Each vial contains a 10 mM DMSO solution, ready for immediate dilution and use. Shipping is performed on blue ice for evaluation samples and at room temperature or on blue ice upon request for larger orders. Upon arrival, compounds should be stored at -20°C for up to 12 months, or -80°C for up to 24 months to maintain stability (product documentation).

Researchers are advised to:

• Check for compound precipitation before use; mix gently if needed.
• Validate final DMSO concentrations in biological assays, typically ≤0.5% v/v.
• Consult the compound annotation file for regulatory status, known targets, and references.
• Include appropriate positive and negative controls in all screens.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a benchmark resource for drug discovery, offering a unique combination of regulatory validation, mechanistic diversity, and workflow readiness. It enables robust pharmacological target identification, drug repositioning, and pathway analysis across multiple disease models. Ongoing research, including recent advances in HDAC6 inhibitor discovery, highlights its translational impact (Song et al., 2023). For further details and ordering information, see the DiscoveryProbe™ FDA-approved Drug Library product page.